Cargando…

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer

BACKGROUND: We explored the predictive significance of BRCA1, TXR1 and TSP1 expression in non-small-cell lung cancer (NSCLC) patients treated with docetaxel in association with cisplatin or gemcitabine. METHODS: To analyse BRCA1, TXR1 and TSP1 mRNA expression from microdissected primary tumours of 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papadaki, C, Tsaroucha, E, Kaklamanis, L, Lagoudaki, E, Trypaki, M, Tryfonidis, K, Mavroudis, D, Stathopoulos, E, Georgoulias, V, Souglakos, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031890/ https://www.ncbi.nlm.nih.gov/pubmed/21157449 http://dx.doi.org/10.1038/sj.bjc.6606027

Ejemplares similares

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
por: Kalikaki, A, et al.
Publicado: (2008)

Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide
por: Karachaliou, Niki, et al.
Publicado: (2013)

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome
por: Saridaki, Z, et al.
Publicado: (2010)

Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
por: Boukovinas, Ioannis, et al.
Publicado: (2008)

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
por: Pallis, A G, et al.
Publicado: (2007)

Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer
por: Sfakianaki, Maria, et al.
Publicado: (2019)

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
por: Souglakos, J, et al.
Publicado: (2008)

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2014)

Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer
por: Santivasi, W L, et al.
Publicado: (2015)

Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients
por: Fajac, A, et al.
Publicado: (2010)

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin
por: Tiseo, M, et al.
Publicado: (2013)

BRCA1 tumours correlate with a HIF-1α phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression
por: Yan, M, et al.
Publicado: (2009)

Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer
por: Balgkouranidou, I, et al.
Publicado: (2014)

Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers
por: Clarke, C L, et al.
Publicado: (2006)

Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2(nd) Line Cetuximab-Based Therapy of Colorectal Cancer Patients
por: Saridaki, Zacharenia, et al.
Publicado: (2011)

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
por: Souglakos, J, et al.
Publicado: (2009)

DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers
por: Kotsopoulos, J, et al.
Publicado: (2007)

Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients
por: Goebel, G, et al.
Publicado: (2012)

TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome
por: Journe, F, et al.
Publicado: (2011)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Evaluation of models to predict BRCA germline mutations
por: Kang, H H, et al.
Publicado: (2006)

Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma
por: Végran, F, et al.
Publicado: (2009)

SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma
por: El Hajj, P, et al.
Publicado: (2015)

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen
por: Wei, J, et al.
Publicado: (2008)

Membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT
por: Roundhill, E, et al.
Publicado: (2013)

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
por: Xu, C-F, et al.
Publicado: (2010)

Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients
por: El Hajj, P, et al.
Publicado: (2013)

RBM38 is involved in TGF-β-induced epithelial-to-mesenchymal transition by stabilising zonula occludens-1 mRNA in breast cancer
por: Wu, Jing, et al.
Publicado: (2017)

Cancer-associated oxidoreductase ERO1-α drives the production of VEGF via oxidative protein folding and regulating the mRNA level
por: Tanaka, Tsutomu, et al.
Publicado: (2016)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response
por: Al-kaabi, M M, et al.
Publicado: (2015)

Role of SNTA1 in Rac1 activation, modulation of ROS generation, and migratory potential of human breast cancer cells
por: Bhat, H F, et al.
Publicado: (2014)

Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer()
por: Matikas, Alexios, et al.
Publicado: (2017)

Impact of differential cyclin D1 expression and localisation in prostate cancer
por: Comstock, C E S, et al.
Publicado: (2007)

Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study
por: Papadaki, Chara, et al.
Publicado: (2020)

mRNA profiling of the cancer degradome in oesophago–gastric adenocarcinoma
por: Baren, J P, et al.
Publicado: (2012)

mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (hTERT) in intracranial tumours of patients in the island of Crete
por: Yannopoulos, A, et al.
Publicado: (2005)

Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer
por: Ohotski, J, et al.
Publicado: (2012)

The collagenase-1 (MMP-1) gene promoter polymorphism - 1607/2G is associated with favourable prognosis in patients with colorectal cancer
por: Hettiaratchi, A, et al.
Publicado: (2007)

Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells
por: Liau, S-S, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_bn74d6b5s2huo8omj7t1r04k2r